Cargando…
Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs
Chemogenetics uses engineered proteins that are controlled by small molecule actuators, allowing in vivo functional studies of proteins with temporal and dose control, and include Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). One major class of DREADDs are mutated muscarinic...
Autores principales: | van der Peet, Phillip L., Gunawan, Christian, Abdul-Ridha, Alaa, Ma, Sherie, Scott, Daniel J., Gundlach, Andrew L., Bathgate, Ross A.D., White, Jonathan M., Williams, Spencer J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053635/ https://www.ncbi.nlm.nih.gov/pubmed/30038895 http://dx.doi.org/10.1016/j.mex.2018.03.003 |
Ejemplares similares
-
The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice
por: Manvich, Daniel F., et al.
Publicado: (2018) -
DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based
DREADDs in Vitro and in Vivo
por: Thompson, Karen J., et al.
Publicado: (2018) -
Protocol for evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative bacterial vector
por: Chan-Hyams, Jasmine V.E., et al.
Publicado: (2020) -
Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice
por: Jendryka, Martin, et al.
Publicado: (2019) -
PHARMIP: An insilico method to predict genetics that underpin adverse drug reactions
por: Zidan, Ahmad M., et al.
Publicado: (2019)